However, TNFAIP3 mutation significantly predicted poor OS in T‐ALL patients (HR = 4.63; 95% CI: 1.79–11.96; 3‐year OS: 0% vs. 39%; p < 0.001) and a short 3‐year RMST [9 (95% CI: 3–14) vs. 23 (95% CI: 19–28) months] in the chemotherapy subgroup (Figure 3B), but it was not significantly associated with OS and 3‐year RMST in the HSCT subgroup (p = 0.814; Figure 3C). The gene discussed is TNFAIP3; the disease is acute lymphoblastic leukemia.